.svg)
.jpg)
Oral solid medicines account for the majority of prescriptions globally due to their stability, ease of administration, and cost efficiency. At the same time, the science behind each oral solid dosage form continues to evolve rapidly. According to Grand View Research, the global oral solid dosage contract manufacturing market reached $38.6 billion in 2024 and is projected to reach $54.7 billion by 2030.
For pharmaceutical companies, converting an active pharmaceutical ingredient into a scalable oral solid dosage form involves far more than selecting a tablet or capsule format. Physicochemical properties, bioavailability constraints, manufacturing scalability, and regulatory expectations all influence oral dosage formulation strategy and commercial feasibility.
As pipelines include more poorly soluble and highly potent molecules, the pathway from molecule to market demands careful alignment between formulation science, process development, and manufacturing infrastructure.
Oral dosage formulation development begins with a detailed understanding of active pharmaceutical ingredients. Properties such as LogP, pKa, solubility, and permeability guide decisions on delivery strategies and processing methods.
Many new small molecules fall within the Biopharmaceutics Classification System (BCS) Class II or IV, where poor aqueous solubility limits absorption. In such cases, the formulation must improve dissolution while maintaining manufacturability and stability.
Poor flow properties can disrupt blending and tableting operations. High cohesion often leads to inconsistent content uniformity, compromising batch reproducibility. Formulation teams address these issues through particle engineering, excipient optimisation, and process adjustments.
Bioavailability remains a central consideration. A formulation that performs well in early studies must also scale into commercial manufacturing without altering the product’s pharmacokinetic profile. When formulation changes occur between clinical phases, developers must conduct bridging studies that add time and cost to development programmes.
Commercial viability also influences formulation decisions. High excipient loads, specialised processing steps, or expensive technologies may achieve bioavailability targets but affect the cost of goods or manufacturing efficiency. These trade-offs shape decisions early in development.
Selecting the right oral dosage formulation strategy requires balancing development speed with long-term scalability.
For BCS Class II compounds, formulators often apply approaches such as particle size reduction, surfactant systems, salt formation, or amorphous solid dispersions. Techniques such as spray drying or hot melt extrusion help stabilise poorly soluble molecules in a higher-energy amorphous state, improving dissolution.
Cyclodextrin complexation also enhances solubility by forming molecular inclusion complexes that increase drug dispersion in gastrointestinal fluids.
BCS Class III and IV molecules introduce additional challenges. Limited permeability across the gastrointestinal epithelium can restrict systemic exposure even when solubility improves. Lipid-based delivery systems and permeation enhancers can facilitate absorption by interacting with endogenous lipid transport pathways.
Development teams often initiate early clinical studies using simplified oral dosage formulations such as capsule-filled API or basic solid dispersions. This approach allows rapid entry into phase I trials. However, inadequate exposure may require reformulation later in development, creating regulatory and manufacturing challenges.
Some sponsors therefore establish a more robust formulation strategy earlier in development when biopharmaceutical risks appear significant.
Excipient compatibility plays an equally important role. Functional excipients influence dissolution, compressibility, stability, and shelf life. Selecting polymers with suitable pH responsiveness or crystallisation inhibition properties can significantly influence performance.
Release profile design also shapes therapeutic outcomes. Immediate-release systems deliver rapid onset, while modified-release tablets regulate drug exposure over extended periods. As discussed in our earlier article on patient-centric dosage design, these delivery profiles increasingly align with adherence goals and disease-specific dosing patterns.
A formulation that performs well in laboratory conditions must also translate into a robust manufacturing process.
Granulation method selection often defines downstream manufacturability. Direct compression suits APIs with favourable flow and compressibility. Wet granulation improves uniformity when powder properties present blending challenges. Dry granulation offers an alternative when moisture sensitivity limits processing options.
Process parameters such as blending time, compression force, and drying conditions influence critical quality attributes including content uniformity, hardness, and dissolution performance.
Scale-up from pilot batches to commercial production introduces additional variables. Equipment geometry, mixing efficiency, and heat transfer characteristics change with batch size. Without careful process development, these factors may alter dissolution profiles or tablet hardness during larger production runs.
Regulatory expectations require clear demonstration that commercial batches maintain the same quality attributes observed in clinical materials. Failure to maintain equivalence can delay regulatory filings or require additional validation work.
Advanced process analytical tools strengthen manufacturing control. Techniques such as near-infrared spectroscopy allow real-time monitoring of blend uniformity and content distribution. Laser-based particle size analysis and terahertz coating measurements help manufacturers maintain tighter control over critical quality attributes.
These technologies reduce reliance on post-process sampling and support consistent product quality across commercial-scale production.
New delivery formats continue to expand the capabilities of oral drug products. Among these innovations, oral thin strips represent an important extension of oral solid dosage technology.
These film-based systems dissolve rapidly in the mouth, delivering medication without the need for water. This property makes them suitable for patients who experience difficulty swallowing conventional tablets.
Manufacturing oral thin strips requires precise control over film thickness, drug distribution, and drying conditions to ensure uniform dosing. Variations in film casting or solvent removal can affect content uniformity and stability.
Despite these challenges, oral thin films offer significant advantages for therapies where adherence plays a critical role. Applications include central nervous system treatments, pediatric medicines, and therapies where rapid onset improves patient outcomes.
Companies with specialised expertise in oral thin film technology can integrate these products into existing oral dosage manufacturing platforms while maintaining regulatory and quality requirements.
For many pharmaceutical companies, internal manufacturing capacity alone cannot address the formulation and production demands associated with complex oral dosage form development.
Contract development and manufacturing organisations provide access to specialised equipment, technical expertise, and established quality systems without requiring major capital investment in new facilities.
By working with experienced partners, developers gain immediate access to validated manufacturing infrastructure and skilled formulation scientists. This arrangement reduces the time required to establish processes and supports faster progression through clinical phases.
CDMOs also help address common development barriers such as scale-up challenges, technology transfer, and regulatory documentation. Integrated development-to-commercial manufacturing capabilities allow smoother transitions between clinical supply and market launch.
Flexible manufacturing capacity also supports portfolio expansion or regional supply strategies, particularly when companies must manage multiple product launches simultaneously.
Developing differentiated oral solid dosage (OSD) products increasingly requires delivery technologies that improve patient adherence, enable rapid absorption, and expand lifecycle opportunities for existing molecules.
ZIM Labs integrates formulation expertise with specialised oral thin film (OTF) technology, enabling pharmaceutical companies to develop differentiated oral solid dosage formats beyond conventional tablets and capsules. The company’s Thinoral® technology supports fast-dissolving oral thin films that are instantly wettable, rapidly dissolving, and compatible with both solid and liquid APIs. These oral thin strips can incorporate taste-masking approaches and nanotechnology-based formulations, enabling effective delivery of challenging or poorly soluble molecules.
ZIM Labs also develops mucoadhesive and sublingual film platforms such as MucoStrip®, designed to release drugs through the buccal or sublingual mucosa. This route can bypass first-pass hepatic metabolism and support faster systemic absorption, which is particularly relevant for therapies requiring rapid onset of action.
Additional innovations, including bilayer oral thin film technology and nanotechnology-enabled platforms such as Spinoral®, enable the delivery of multiple APIs in a single dosage form and improve bioavailability for poorly soluble compounds.
By combining advanced OTF platforms with scalable manufacturing capabilities, ZIM Labs enables pharmaceutical companies to develop patient-friendly, differentiated oral products while maintaining manufacturing efficiency and regulatory readiness.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
